Our data shows that ERBB2 inhibition affected the antigen-presenting and processing machinery including peptide transporters as TAP1 and TAP234 and directly the expression of MHC-I, but did not rise evidence to regulate neuroendocrine features of SCLC cells. Here, TAP1 is linked to small cell lung carcinoma.